Thoughts from Datavant leaders on the evolving health data landscape

Datavant Webinars

Learn more about the healthcare data ecosystem and real world data

Upcoming Webinar

June 16, 2021 1:00pm ET

Reduce Patient Burden and Improve Outcomes with Real World Data

Tyler Pugsley
Tyler Pugsley
Vice President of Life Sciences
Ardy Arianpour
Ardy Arianpour
CEO & Co-Founder
Devin Gilliam
Devin Gilliam
Business Development, Clinical Trials
Christopher P. Boone, PhD, FACHE, FHIMSS
Christopher P. Boone, PhD, FACHE, FHIMSS
VP, Global Head of Health Economics & Outcomes Research


Today, the multiple disparate touch points required for clinical research are burdensome for patients, sites and sponsors. Patient engagement, recruitment, and surveillance for trials are crucial to unlocking these challenges and expanding research access. In this discussion, Medable, Datavant, Seqster, and Abbvie will illustrate examples of successful application of novel technologies within clinical trials to enhance the patient journey and improve time to treatment.

Join speakers from Medable, Datavant, Seqster, and Abbvie as they share:

  • A secure, patient-centric, and real-time data connectivity approach to clinical trials
  • Successful clinical and commercial applications of Datavant, Seqster, and Medable technologies
  • Solutions that transform each step of the patient journey from pre-clinical to post-clinical experience
  • How to improve patient engagement, recruitment, and longitudinal surveillance

Webinars On-Demand

play button large

Oncology Experts Panel: How Real-World Data Propels Innovation in R&D Commercialization, and Beyond

In this conversation moderated by Vera Mucaj, Head of Trials and Chief Scientist at Datavant, our panelists will share how they’re thinking about current trends and future needs in oncology and RWD, including:

  • Using RWD endpoints in oncology clinical development and beyond
  • Considerations around the use of novel data sources (e.g., genomic data)
  • The role of RWD in step-change innovation across the oncology clinical development and commercial lifecycle (e.g., seamless trials, increased diversity in recruitment, improving patient access)
play button large

Real-World Data and Patient Privacy: What They Didn’t Teach You About Expert Determination & HIPAA

In this session co-hosted by Datavant and Mirador Analytics, we’ll share:

  • Why Expert Determination is a critical step in using and connecting health data
  • How to avoid common pitfalls and delays in joining de-identified data across organizations
  • How to retain the maximize utility of data while still protecting privacy
play button large

The Value of Linked Datasets in Rare Genetic Disease Research

In this discussion, Datavant and Dr. Michael Kruer of Phoenix Children’s Hospital, Dr. Jacob Kean of the University of Utah, and Paul Gross, founder of the CP Research Network will share:

  • An overview of the CP Research Network and how they are transforming CP care utilizing fit-for-purpose clinical registry data
  • CP Research Network’s vision for enabling research and quality data embedded in the EMR
  • How to unlock the discovery of genetic causes for CP and other rare diseases by linking real-world datasets
play button large

Seqster Spotlight: The Value of a Patient-Centric & Real-Time Approach to Real-World Data

Eliminating healthcare data silos is not only important for healthcare institutions but can also improve the patient experience and their health in real-time. To reduce friction, and increase connectivity within healthcare, Seqster provides instant interoperability to retrieve and harmonize electronic health records (EHR), genetic data, and continuous monitoring data from distinct sources. Seqster pioneered patient-centric, longitudinal health records – incorporating EHR information, genomic (DNA) profiles, wearable device data with end-to-end solutions.

Through licenses to life science enterprise customers, as well as providers and payers, Seqster’s healthcare technology platform connects at least 3,600 healthcare providers and more than 150,000 hospitals and clinics in the U.S., and combine that information with their DNA and other real-time fitness wearable data in a HIPAA- and FDA 21 CFR PART 11-compliant, multi-cloud platform. Seqster is also compliant with new CMS and ONC 21st Century Cures Act rules. The platform’s unique capabilities lead to an engaging user experience and improved health outcomes while reducing cost and administrative burden.

In this discussion moderated by Datavant, guest speaker from Seqster will share:

  • An overview of Seqster’s unique capabilities and approach to health data connectivity\
  • Importance of real-time and patient-centric approach for health data in clinical trials
  • Real-world examples and case studies of Seqster’s unique capabilities in life sciences
play button large

Demystifying Mortality Data for Critical COVID-19 Insights

In this discussion, join Datavant, A3.AI, and the Columbia University Actuarial Science Program to learn more about the following topics:

  • Overview of access to and capabilities of mortality data
  • A3.AI’s innovative approach to COVID-19 insights and advanced analytical techniques using mortality and real-world data
  • The Columbia Actuarial Science Program analysis of the Death Index and their insights regarding this data source’s utility for actuarial analyses
  • Opportunities and challenges associated with utilizing mortality data for research and analysis
play button large

Optimizing Real-World Data for Synthetic & External Control Arms

In this panel discussion moderated by Datavant, and featuring experts from Ikaika Health, Verantos, and Kantar Health to answer critical questions such as:

  • What are examples of successful synthetic or external control arms?

  • What are the best practices for utilizing real-world evidence for synthetic control arms?

  • How can solutions and innovations in the trial space improve synthetic control arm design and execution?

play button large

Getting the Edge in Your Data Strategy: The Key to Dismantling Pharma’s Data Silos

In this webinar, speakers from ZS and Datavant will discuss:

  • How RWE and commercial teams can benefit from linking both third-party and proprietary data across their organization
  • Examples of using linked data to better understand the patient journey and outcomes for specialty products
  • Best practices for linking data across your organization
play button large

Insights from BHI: Intersection of Behavioral Health & Chronic Medical Conditions

In this webinar, you will learn:

  • An overview of BHI and the type of data and analytic solutions offered
  • Unique case studies and examples of the capabilities of closed claims data
  • Insights and analysis on chronic conditions
play button large

The Value of Real-World Data in Clinical Trials

In this webinar, you will learn:

  • What are examples of successful applications of real-world data in clinical trials? And, what role has COVID-19 played in reshaping this?
  • What are the best practices for incorporating real-world data into clinical trials, including addressing privacy and patient consent?
  • How can solutions and innovations in the trial space improve the utilization and adoption of real-world data?
play button large

Insights from Quest Diagnostics: COVID-19 and Beyond

In this webinar, you will learn:

  • An overview of Quest Diagnostics and types of testing offered
  • Fit-for-purpose value of lab/testing data for healthcare and life sciences organizations
  • Insights drawn from analysis of the COVID-19 testing data
play button large

Using Fit-for-Purpose EHR Data to Understand COVID-19

In this webinar, you will learn:

  • An overview of EHR data and its fit-for-purpose value in understanding treatment decisions and impact on patient outcomes
  • Examples of how EHR data is being used to better understand gaps in care and further personalize care for patients
  • The value of EHR data linked with other real-world data, such as claims, in gaining a more complete understanding of patients for COVID-19 research
play button large

Enriching Patient Journey Insights with Lab data

In this webinar, you will learn:

  • The value of a unique clinically smart platform to execute cohorts faster and more precisely
  • How to access key datasets (e.g. lab data, medical and pharmacy claims) with greater agility to fine tune and iterate cohorts
  • How to glean more clinically relevant insights to understand brand eligibility for patients at a specific point in their journey
play button large

Using Fit-for-Purpose Real-World Data to Enhance Our Understanding of COVID-19

In this webinar we will provide an overview of how linking real-world data across institutions is necessary to accelerate COVID-19 research.

We will share the goals and current progress of the COVID-19 Research Database effort, including recent research findings, and present ways for patients and the broader patient advocacy community to participate.

Learn more about the COVID-19 Research Database here.

play button large

What an open data ecosystem can do for clinical development

In this webinar, we discussed recent progress in clinical development, particularly given the FDA’s push to incorporate real world data for protocol feasibility analysis, hybrid trial design, patient recruitment, and running post-marketing surveillance studies. We explained why an open data ecosystem is essential for those efforts – that is, a data ecosystem where parties can bilaterally exchange and connect data for a variety of use cases while complying with regulations and protecting individual patient privacy; and we discussed some of the work that Parexel and Datavant are doing together to help accelerate progress in the space.

play button large

Specialty Pharmacy Data Aggregation: Opportunities & Challenges Webinar

In this webinar we will provide an overview of specialty pharmacy data, tracing the patient journey to understand the data being generated and how it flows. We’ll highlight the opportunities and challenges associated with aggregating specialty pharmacy data, and discuss examples of how aggregated data can be used to better understand patient adherence and market access at the brand level.